Indian drugmakers oppose a proposal making them solely liable for medicine overpricing. This regulatory move exempts retail chemists, hospitals, and nursing homes from penalties. Pharmaceutical groups argue this unfairly burdens manufacturers already following pricing rules. Retail chemists, however, welcome the safeguards for their members. Manufacturers believe accountability should extend to those setting the final patient price.